Featuring an interview with Dr Natalie Vokes, including the following topics:

• Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00)
  • Ohara S et al. Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study. JTO Clin Res Rep 2024;6(3):100762. Abstract
  • Masuda K et al. MRDSEEKER (JCOG2111A): A prospective study to evaluate MRD and its association with prognosis in curative-intent NSCLC. World Conference on Lung Cancer 2025;Abstract P3.18.04.
  • Zhou C et al. IMpower010: Biomarkers of disease-free survival in a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO IO 2021;Abstract 2O.
• MRD analysis of adjuvant therapy with osimertinib for resected EGFR-mutated Stage IB to IIIA non-small cell lung cancer (NSCLC) (8:28)
  • Herbst RS et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med 2025;31(6):1958-68. Abstract
• MRD analyses of perioperative chemoimmunotherapy for resected NSCLC (15:12)
  • Forde PM et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med 2025;393(8):741-52. Abstract
• ctDNA dynamics in advanced NSCLC treated with immunotherapy (20:56)
  • Vokes NI et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo). ASCO 2023;Abstract 9022.
  • Anagnostou V et al. ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nat Med 2023;29(10):2559-69. Abstract
  • Anagnostou V et al. A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). ASCO 2025;Abstract TPS8669.

CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics:

• Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00)
• Potential role of thymidine kinase testing in monitoring response to therapy (4:56)
• Interpretation of next-generation sequencing testing; use of targeted therapy (10:59)
• Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19)
• Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07)
• Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15)
• Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26)
• Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10)
• Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31)
• Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36)
• Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics:

• Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00)
• Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21)
• Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56)
• Appropriate timing for assessment of ESR1 and PI3K pathway alterations (17:34)
• Evolving guidelines for routine biomarker evaluation (21:37)
• Implications of precision oncology clinical trials for future biomarker utility (25:07)
• Summary, key questions, future directions (33:09)

CME information and select publications